Eli Lilly & Co.(LLY)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $623.78 – $1249.45
- YTD
- +10.71%
- IV Rank (30D)
- 58.15
- Straddle Price
- $117.47
- P/C Vol Ratio
- 0.87
- Market Cap
- $1057.5B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.63% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 10.13% (VRP-adj) |
| WACC | 9.87% |
| Volatility Risk Premium | +27.5pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 18.8% |
| Rev. Growth (YoY, DCF input) | +27.3% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $11.8B |
| Return on Equity (TTM) | 81.0% |
| Book / Price | 2.9% |
| Gross Margin (TTM) | 82.8% |
| FCF Margin (TTM) | 16.4% |
| Debt / Equity | 1.26 |
| Quality Score | 5/6 — high quality (12y DCF) |
| SMA 50 | $1125.21 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1186.71 |
| Bollinger Width / SMA20 | 0.8% (drives anchor stability) |
| Net Debt | $34.1B |
| Market Cap | $1065B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $818.33 | 19% | |
| DDM (Gordon) | $167.63 | 0% | |
| Peer P/E | $845.03 | 9% | median 27.3× · 8 peers |
| Peer EV/EBITDA | $720.05 | 9% | median 17.1× · 8 peers |
| Peer P/B | $214.60 | 2% | median 6.2× · 7 peers |
| Peer P/S | $414.42 | 6% | median 4.7× · 8 peers |
| Market Anchor (SMA50) | $1125.21 | 38% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $1128.89 | 19% | 115 strikes · skew +1.15 |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNYS
- Market Cap
- $1057.5B
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +0.59% | 23 |
| Feb | -0.61% | 23 |
| Mar | +1.39% | 23 |
| Apr | +2.77% | 23 |
| May | +2.03% | 23 |
| Jun | +2.58% | 23 |
| Jul | +0.83% | 23 |
| Aug | +0.90% | 22 |
| Sep | -0.21% | 23 |
| Oct | -1.24% | 23 |
| Nov | +2.03% | 23 |
| Dec | +3.73% | 23 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-08 | Pre-Market | 7.68% | 10.51% | 1.37x | Exceeded |
| 2024-10-30 | Pre-Market | 6.10% | 6.84% | 1.12x | Exceeded |
| 2025-02-06 | Pre-Market | 5.25% | 2.90% | 0.55x | Within |
| 2025-05-01 | Pre-Market | 5.18% | 11.47% | 2.21x | Exceeded |
| 2025-08-07 | Pre-Market | 6.50% | 13.87% | 2.13x | Exceeded |
| 2025-10-30 | Pre-Market | 5.56% | 4.17% | 0.75x | Within |
| 2026-02-04 | Pre-Market | 7.13% | 10.83% | 1.52x | Exceeded |
| 2026-04-30 | Pre-Market | 6.39% | 9.58% | 1.50x | Exceeded |
- IV Rank (30D)
- 58.15
- IV Rank (7D)
- 93.8
- Avg IV
- 52.9%
- Straddle (30D)
- $117.47
- Straddle (7D)
- $40.92
- P/C Volume
- 0.87
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.40
- Correlation (SPY)
- 13.3%
- R²
- 0.02
- Ann. Volatility
- 38.6%
- SPY Volatility
- 12.7%
Low volatility - stock moves less than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $2.95B | 28.84% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $1.58B | 15.46% | 2026-03-31 |
| 3 | JANE STREET GROUP, LLC Custodian | $1.36B | 13.24% | 2026-03-31 |
| 4 | IMC-Chicago, LLC Custodian | $818.41M | 7.99% | 2026-03-31 |
| 5 | WOLVERINE TRADING, LLC Custodian | $665.77M | 6.50% | 2025-09-30 |
| 6 | JPMORGAN CHASE & CO Custodian | $342.15M | 3.34% | 2026-03-31 |
| 7 | GROUP ONE TRADING LLC Custodian | $299.39M | 2.92% | 2026-03-31 |
| 8 | GOLDMAN SACHS GROUP INC Custodian | $230.68M | 2.25% | 2026-03-31 |
| 9 | BNP PARIBAS FINANCIAL MARKETS Custodian | $195.08M | 1.90% | 2026-03-31 |
| 10 | D. E. Shaw & Co., Inc. Custodian | $170.80M | 1.67% | 2026-03-31 |
| 11 | UBS Group AG Custodian | $143.75M | 1.40% | 2026-03-31 |
| 12 | PEAK6 LLC | $138.43M | 1.35% | 2026-03-31 |
| 13 | MILLENNIUM MANAGEMENT LLC Custodian | $122.24M | 1.19% | 2026-03-31 |
| 14 | BlackRock, Inc. Custodian | $103.93M | 1.01% | 2026-03-31 |
| 15 | SIMPLEX TRADING, LLC Custodian | $102.28M | 1.00% | 2026-03-31 |
| 16 | Qube Research & Technologies Ltd | $85.35M | 0.83% | 2026-03-31 |
| 17 | TORONTO DOMINION BANK | $82.78M | 0.81% | 2026-03-31 |
| 18 | Marex Group plc | $68.98M | 0.67% | 2026-03-31 |
| 19 | Eisler Capital Management Ltd. | $68.17M | 0.67% | 2025-09-30 |
| 20 | Man Group plc | $64.02M | 0.63% | 2026-03-31 |
| 21 | CITIGROUP INC Custodian | $61.81M | 0.60% | 2026-03-31 |
| 22 | LMR Partners LLP | $52.70M | 0.51% | 2026-03-31 |
| 23 | VestGen Advisors, LLC | $49.49M | 0.48% | 2026-03-31 |
| 24 | Centiva Capital, LP | $49.21M | 0.48% | 2026-03-31 |
| 25 | Walleye Trading LLC | $49.02M | 0.48% | 2026-03-31 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $3.21B | 22.55% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $1.83B | 12.90% | 2026-03-31 |
| 3 | CITADEL ADVISORS LLC Custodian | $1.45B | 10.23% | 2026-03-31 |
| 4 | IMC-Chicago, LLC Custodian | $1.18B | 8.33% | 2026-03-31 |
| 5 | WOLVERINE TRADING, LLC Custodian | $675.58M | 4.75% | 2025-09-30 |
| 6 | BARCLAYS PLC Custodian | $537.24M | 3.78% | 2026-03-31 |
| 7 | CITIGROUP INC Custodian | $530.89M | 3.73% | 2026-03-31 |
| 8 | WELLS FARGO & COMPANY/MN Custodian | $471.57M | 3.32% | 2026-03-31 |
| 9 | MILLENNIUM MANAGEMENT LLC Custodian | $458.51M | 3.22% | 2026-03-31 |
| 10 | BNP PARIBAS FINANCIAL MARKETS Custodian | $405.62M | 2.85% | 2026-03-31 |
| 11 | UBS Group AG Custodian | $364.32M | 2.56% | 2026-03-31 |
| 12 | GOLDMAN SACHS GROUP INC Custodian | $355.77M | 2.50% | 2026-03-31 |
| 13 | D. E. Shaw & Co., Inc. Custodian | $317.32M | 2.23% | 2026-03-31 |
| 14 | GROUP ONE TRADING LLC Custodian | $294.14M | 2.07% | 2026-03-31 |
| 15 | Marex Group plc | $183.95M | 1.29% | 2026-03-31 |
| 16 | JPMORGAN CHASE & CO Custodian | $177.68M | 1.25% | 2026-03-31 |
| 17 | LMR Partners LLP | $165.83M | 1.17% | 2026-03-31 |
| 18 | Squarepoint Ops LLC | $136.77M | 0.96% | 2026-03-31 |
| 19 | Qube Research & Technologies Ltd | $131.34M | 0.92% | 2026-03-31 |
| 20 | 683 Capital Management, LLC | $123.25M | 0.87% | 2026-03-31 |
| 21 | Eisler Capital Management Ltd. | $103.20M | 0.73% | 2025-09-30 |
| 22 | CAPSTONE INVESTMENT ADVISORS, LLC | $87.65M | 0.62% | 2026-03-31 |
| 23 | MARSHALL WACE, LLP Custodian | $75.97M | 0.53% | 2026-03-31 |
| 24 | Centiva Capital, LP | $68.98M | 0.48% | 2026-03-31 |
| 25 | CREDIT AGRICOLE S A | $68.06M | 0.48% | 2026-03-31 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-21 | Ralph Alvarez | Director | Award (A) | +10 | $1146.90 | $12.4K | EDGAR |
| 2026-07-21 | JUAN R LUCIANO | Director | Award (A) | +13 | $1146.90 | $15.9K | EDGAR |
| 2026-07-21 | J Erik Fyrwald | Director | Award (A) | +8 | $1146.90 | $9.9K | EDGAR |
| 2026-07-21 | Gabrielle Sulzberger | Director | Award (A) | +4 | $1146.90 | $5.0K | EDGAR |
| 2026-06-16 | J Erik Fyrwald | Director | Award (A) | +8 | $1129.35 | $9.9K | EDGAR |
| 2026-06-16 | JUAN R LUCIANO | Director | Award (A) | +14 | $1129.35 | $15.9K | EDGAR |
| 2026-06-16 | Ralph Alvarez | Director | Award (A) | +10 | $1129.35 | $12.4K | EDGAR |
| 2026-06-16 | Gabrielle Sulzberger | Director | Award (A) | +4 | $1129.35 | $5.0K | EDGAR |
| 2026-06-11 | Ilya Yuffa | EVP&Pres, LLY USA&Global Capab | Sell (S) | −2,500 | $1150.77 | -$2.88M | EDGAR |
| 2026-05-19 | Ralph Alvarez | Director | Award (A) | +12 | $988.09 | $12.4K | EDGAR |
| 2026-05-19 | J Erik Fyrwald | Director | Award (A) | +10 | $988.09 | $9.9K | EDGAR |
| 2026-05-19 | JUAN R LUCIANO | Director | Award (A) | +16 | $988.09 | $15.9K | EDGAR |
| 2026-05-19 | Gabrielle Sulzberger | Director | Award (A) | +5 | $988.09 | $5.0K | EDGAR |
| 2026-05-07 | LILLY ENDOWMENT INC | Sell (S) | −15,828 | $995.36 | -$15.75M | EDGAR | |
| 2026-04-21 | Ralph Alvarez | Director | Award (A) | +13 | $919.90 | $12.4K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | LILLY ENDOWMENT INC | 10%+ Owner | 91,883,358 | $109.90B | -$111.13B | 447 | 2026-05-07 |
| 2 | David A Ricks | President, Chair, and CEO | 579,023 | $692.53M | $384.2K | 42 | 2026-02-11 |
| 3 | JOHN C LECHLEITER | Chairman, President and CEO | 457,528 | $547.22M | $1.00M | 28 | 2017-12-13 |
| 4 | SIDNEY TAUREL | Chairman | 441,806 | $528.41M | -$1.50M | 7 | 2009-01-09 |
| 5 | Jan M Lundberg | EVP,Science&Tech and Pres. LRL | 199,212 | $238.26M | -$10.83M | 20 | 2018-02-13 |
| 6 | Enrique A Conterno | SVP&Pres, LillyDiab & LillyUSA | 163,121 | $195.10M | -$13.33M | 43 | 2019-02-20 |
| 7 | Daniel Skovronsky | EVP, CS&PO & Pres. LRL | 162,781 | $194.69M | -$2.28M | 20 | 2026-02-11 |
| 8 | ROBERT A ARMITAGE | Sr. VP and General Counsel | 154,858 | $185.21M | -$1.24M | 12 | 2012-02-02 |
| 9 | Stephen F Fry | SVP, HR & Diversity | 152,812 | $182.77M | -$5.86M | 29 | 2022-02-11 |
| 10 | Bryce D. Carmine | EVP and Pres, Lilly Bio-Meds | 145,979 | $174.60M | -$2.67M | 22 | 2012-02-02 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | LILLY ENDOWMENT, INC. | Shareholder | 310,000 | $372.02M | 2026-07-07 | Fidelity Capital Markets | — | EDGAR |
| 2026-06-26 | LILLY ENDOWMENT, INC. | Shareholder | 305,000 | $343.95M | 2026-06-26 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-06-10 | Yuffa Ilya | Officer | 2,500 | $2.88M | 2026-06-10 | THE CHARLES SCHWAB CORPORATION | 10b5-1 | EDGAR |
| 2026-05-28 | LILLY ENDOWMENT, INC. | Shareholder | 310,000 | $335.71M | 2026-05-28 | Fidelity Capital Markets | — | EDGAR |
| 2026-05-22 | LILLY ENDOWMENT, INC. | Shareholder | 300,000 | $312.50M | 2026-05-22 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-05-20 | LILLY ENDOWMENT, INC. | Shareholder | 305,000 | $311.53M | 2026-05-20 | Fidelity Capital Markets | — | EDGAR |
| 2026-05-06 | LILLY ENDOWMENT, INC. | Shareholder | 300,000 | $296.66M | 2026-05-06 | J.P. Morgan Securities LLC | — | EDGAR |
| 2025-12-23 | LILLY ENDOWMENT, INC. | 10% Stockholder | 300,000 | $322.94M | 2025-12-23 | Fidelity Capital Markets | — | EDGAR |
| 2025-11-24 | LILLY ENDOWMENT, INC. | 10% Stockholder | 305,000 | $323.21M | 2025-11-24 | Fidelity Capital Markets | — | EDGAR |
| 2025-11-19 | LILLY ENDOWMENT, INC. | 10% Stockholder | 310,000 | $319.32M | 2025-11-19 | J.P. Morgan Securities LLC | — | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-20 | 0001193125-26-232707 | EDGAR |
| 2026-05-07 | 0000059478-26-000048 | EDGAR |
| 2026-04-30 | 0000059478-26-000043 | EDGAR |
| 2026-02-04 | 0000059478-26-000008 | EDGAR |
| 2025-11-21 | 0000059478-25-000271 | EDGAR |
| 2025-10-30 | 0000059478-25-000251 | EDGAR |
| 2025-08-20 | 0001193125-25-184093 | EDGAR |
| 2025-08-07 | 0000059478-25-000202 | EDGAR |
| 2025-05-08 | 0000059478-25-000138 | EDGAR |
| 2025-05-01 | 0000059478-25-000129 | EDGAR |
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-30 | 0000059478-26-000045 | EDGAR |
| 2025-10-30 | 0000059478-25-000254 | EDGAR |
| 2025-08-07 | 0000059478-25-000204 | EDGAR |
| 2025-05-01 | 0000059478-25-000132 | EDGAR |
| 2024-10-30 | 0000059478-24-000245 | EDGAR |
| 2024-08-08 | 0000059478-24-000187 | EDGAR |
| 2024-04-30 | 0000059478-24-000118 | EDGAR |
| 2023-11-02 | 0000059478-23-000284 | EDGAR |
| 2023-08-08 | 0000059478-23-000221 | EDGAR |
| 2023-04-27 | 0000059478-23-000162 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/E Ratio | 42.5 |
| P/B Ratio | 33.9 |
| P/S Ratio | 14.6 |
| EV/EBITDA | 30.2 |
| TTM Revenue | $72.2B |
| TTM Net Income | $25.3B |
| TTM EPS | $28.15 |
| ROE | 81.0% |
| Dividend Yield | 0.53% |
| Debt/Equity | 1.39 |